Cargando…
A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
Sixteen patients with advanced and recurrent malignant salivary gland tumours were admitted to a randomised trial and the response assessed. Seven patients received Epirubicin/5-Fluorouracil and none of these patients responded. Nine patients received Cisplatinum and only one patient had a partial r...
Autores principales: | Jones, A. S., Phillips, D. E., Cook, J. A., Helliwell, T. R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968228/ https://www.ncbi.nlm.nih.gov/pubmed/7678976 |
Ejemplares similares
-
Combined Cisplatinum and Laser Thermal Therapy for Palliation of Recurrent Head and Neck Tumors
por: Paiva, Marcos B., et al.
Publicado: (2000) -
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
por: Hu, Guofang, et al.
Publicado: (2016) -
Malignant tumours of the salivary glands
por: Bensadoun, R J, et al.
Publicado: (2001) -
Ototoxicity of cisplatinum.
por: Brock, P., et al.
Publicado: (1991) -
A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Publicado: (1990)